Raymond Ruff

Science TLDR

Science EN ↓ 93 Folgen

Ten-minute paper summaries for scientists and experts. Two episodes a week: Mondays feature the top-scoring paper from a curated weekly digest of T cell engager, bispecific antibody, and protein engineering literature. Fridays cover the top trending paper on PubMed — any field, whatever's catching the research community's attention that week. Hosted by Raymond Ruff, a protein scientist working in translational immunotherapeutics. Audio is generated with NotebookLM; the host prompt aims for measured scientific skepticism rather than hype. Feedback and paper suggestions: sciencetldrpod@gmail.com

Besuch unbedingt die Website des Podcasts und unterstütze die Macher: raymondruff.github.io

Autor

Raymond Ruff

Kategorie

Science

Podcast-Website

raymondruff.github.io

Neueste Folge

18. Okt 2026

Wo hören?

Podcasts in der App Replaio Radio Bald verfügbar

Podcasts kommen bald in die App. Installiere sie jetzt und erlebe als Erster einen ganz neuen Blick auf Podcasts

Bei Google Play herunterladen Kostenlos installieren Android fast 10 Mio. Downloads · Bewertung 4,8 iOS bald

Folgen

Lying increases trust in science 26.07.2025

https://doi.org/10.1007/s11186-025-09635-1

Soil and cherry bacterial communities predict flavor on coffee farms 20.06.2025

https://doi.org/10.1038/s41598-025-03665-6

What Is It Like to Be a Bat? 12.06.2025

https://www.jstor.org/stable/2183914

3 Papers on Antibody Tumor Penetration and Clearance 07.06.2025

Mixing it up a little with an episode covering 3 papers on the same topic. Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearancedoi:10.1016/j.addr.2008.04.012. A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumorshttps://doi.org/10.1016/j.ymthe.2022.04.013. Influence of molecular size on tissue dis...

Why people follow rules 03.06.2025

https://doi.org/10.1038/s41562-025-02196-4

Cross-tissue multicellular coordination and its rewiring in cancer 31.05.2025

doi: 10.1038/s41586-025-09053-4

Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity 27.05.2025

https://doi.org/10.1038/s41586-025-08997-x

Deep-learning-based single-domain and multidomain protein structure prediction with D-I-TASSER 26.05.2025

https://doi.org/10.1038/s41587-025-02654-4

Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease 20.05.2025

DOI: 10.1056/NEJMoa2504747

Adversarial testing of global neuronal workspace and integrated information theories of consciousness 02.05.2025

https://www.nature.com/articles/s41586-025-08888-1

Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease 14.04.2025

https://doi.org/10.1038/s41586-025-08852-z

A natural experiment on the effect of herpes zoster vaccination on dementia 07.04.2025

DOI: 10.1038/s41586-025-08800-x

The end of the genetic paradigm of cancer 02.04.2025

https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003052

Embodied large language models enable robots to complete complex tasks in unpredictable environments 30.03.2025

https://www.nature.com/articles/s42256-025-01005-x

Sequencing by Expansion (SBX) – a novel, high-throughput single-molecule sequencing technology 26.03.2025

https://www.biorxiv.org/content/10.1101/2025.02.19.639056v1

CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells 19.03.2025

DOI: 10.1158/2643-3230.BCD-23-0258

AlphaFold prediction of structural ensembles of disordered proteins 21.02.2025

DOI: 10.1038/s41467-025-56572-9 Key Points: - Introduces AlphaFold-Metainference, a new method combining AlphaFold predictions with physics simulations - Notable because AlphaFold was trained on structured proteins but shows surprising accuracy with disordered ones - Validated against experimental data from 11 different disordered proteins using SAXS (small-angle X-ray scattering) - Further valida...

A second-generation M1-polarized CAR macrophage with antitumor efficacy 13.02.2025

DOI: 10.1038/s41590-023-01687-8 Key Points: - Research focuses on using engineered macrophages (CAR-iMACs) instead of typical CAR T cells to fight solid tumors - Started with iPSCs (induced pluripotent stem cells) which were differentiated into macrophages and engineered with CARs - Created two versions: - First generation with CD3ζ domain - Second generation with added TIR domain - Second generat...

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis 12.02.2025

DOI: 10.1056/NEJMoa2410965 Key Points: - Phase 3 trial testing obinutuzumab (anti-CD20 monoclonal antibody) + standard therapy vs placebo + standard therapy for lupus nephritis - Primary endpoint: Complete renal response at week 76 - Notable finding: 46.4% response with obinutuzumab vs 33.1% with placebo (13.4% improvement, p=0.02) Trial Design: - 271 adult patients with active lupus nephritis - R...

Triple knockdown of CD11a, CD49d, and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice 10.02.2025

DOI: 10.1126/scitranslmed.adl6432 Key Points: The Research Problem: CAR-T cell therapy has been successful for blood cancers but faces challenges with solid tumors Major challenge: "On-target, off-tumor toxicity" where CAR-T cells attack healthy tissues Previous patient death case: HER2-targeted CAR-T cells attacked lung tissue due to HER2 expression on lung cells Study Focus: Target: EpCAM (epith...

Deep learning enhances the prediction of HLA class I-presented CD8+ T cell epitopes in foreign pathogens 06.02.2025

DOI: 10.1038/s42256-024-00971-y Key Topics: - New deep learning model MUNIS for predicting CD8+ T-cell epitopes - Implications for vaccine development and personalized medicine - Real-world validation using Epstein-Barr virus (EBV) Background Science: - HLAI molecules display protein fragments (epitopes) on cell surfaces - CD8+ T-cells recognize foreign epitopes to trigger immune response - Tradit...

Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives 05.02.2025

DOI: https://doi.org/10.1186/s40035-025-00465-w Key Discussion Points: 1. Overview of Current Landscape - Three FDA-approved second-generation antibodies: Aducanumab, Lecanemab, Donanemab - Lecanemab recently received traditional FDA approval - Represents validation of amyloid cascade hypothesis 2. Individual Antibody Profiles: Aducanumab - Derived from memory B cells of both healthy and cognitive...

Scratching promotes allergic inflammation and host defense via neurogenic mast cell activation 04.02.2025

DOI: 10.1126/science.adn9390 Key points: The Itch-Scratch Paradox Scratching is an evolutionarily conserved behavior but seems counterproductive as it worsens inflammation Research found scratching serves both harmful and beneficial purposes: Can exacerbate allergic skin conditions Helps protect against bacterial infections like S. aureus Provides insight into why scratching is pleasurable despite...

Prior vaccination prevents overactivation of innate immune responses during COVID-19breakthrough infection 31.01.2025

DOI: 10.1126/scitranslmed.adq1086 Central Idea: This study examines how previous COVID-19 vaccination influences both innate and adaptive immune responses during breakthrough infections. The researchers found that vaccination helps prevent excessive activation of the immune system, particularly in innate immune cells like monocytes and natural killer (NK) cells. Key Concepts: Breakthrough vs Prima...

Accelerated enzyme engineering by machine-learning guided cell-free expression 23.01.2025

DOI: https://doi.org/10.1038/s41467-024-55399-0 Central Idea: This paper presents an ML-guided platform for accelerating enzyme engineering by combining cell-free protein synthesis, functional screening, and machine learning to rapidly optimize enzymes for multiple distinct chemical reactions. The approach is demonstrated by engineering variants of an amide synthetase (McbA) to improve synthesis o...

Höre den Podcast Science TLDR in Replaio

Radio und Podcasts in einer App - kostenlos und ohne Anmeldung. Installiere sie noch heute und verpasse den Start nicht

Bei Google Play herunterladen

Replaio ist kein Herausgeber von Podcasts; die Namen der Sendungen, Cover und Audioinhalte gehören ihren Autoren und werden über öffentliche RSS-Feeds verbreitet